Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy Veracyte stock | 42.82

Own Veracyte stock in just a few minutes.

Posted

Fact checked

Veracyte, Inc is a biotechnology business based in the US. Veracyte shares (VCYT) are listed on the NASDAQ and all prices are listed in US Dollars. Veracyte employs 354 staff and has a trailing 12-month revenue of around USD$112.5 million.

How to buy shares in Veracyte

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Veracyte. Find the stock by name or ticker symbol: VCYT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Veracyte reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$42.82, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Veracyte, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Veracyte. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Veracyte's share price?

Since the stock market crash in March caused by coronavirus, Veracyte's share price has had significant positive movement.

Its last market close was USD$42.82, which is 41.06% up on its pre-crash value of USD$25.24 and 208.06% up on the lowest point reached during the March crash when the shares fell as low as USD$13.9.

If you had bought USD$1,000 worth of Veracyte shares at the start of February 2020, those shares would have been worth USD$625.30 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,589.05.

Veracyte share price

Use our graph to track the performance of VCYT stocks over time.

Veracyte shares at a glance

Information last updated 2020-10-20.
Latest market closeUSD$42.82
52-week rangeUSD$13.9 - USD$44.64
50-day moving average USD$34.4097
200-day moving average USD$29.4707
Wall St. target priceUSD$37.4
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.288

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks
N/A
0%
A free way to invest in stocks, ETFs and crypto.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Tastyworks
$0
Stocks, Options, ETFs, Futures
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Veracyte stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Veracyte price performance over time

Historical closes compared with the close of $42.82 from 2020-10-16

1 week (2020-10-16) 42.82
1 month (2020-09-25) 39.21%
3 months (2020-07-24) 41.18%
6 months (2020-04-24) 82.91%
1 year (2019-10-25) 101.89%
2 years (2018-10-25) 346.51%
3 years (2017-10-25) 409.76%
5 years (2015-10-23) 519.68%

Veracyte financials

Revenue TTM USD$112.5 million
Gross profit TTM USD$83.8 million
Return on assets TTM -7.55%
Return on equity TTM -13.73%
Profit margin -27.49%
Book value $4.483
Market capitalisation USD$2.4 billion

TTM: trailing 12 months

Shorting Veracyte shares

There are currently 3.5 million Veracyte shares held short by investors – that's known as Veracyte's "short interest". This figure is 0.7% down from 3.5 million last month.

There are a few different ways that this level of interest in shorting Veracyte shares can be evaluated.

Veracyte's "short interest ratio" (SIR)

Veracyte's "short interest ratio" (SIR) is the quantity of Veracyte shares currently shorted divided by the average quantity of Veracyte shares traded daily (recently around 444928.00511509). Veracyte's SIR currently stands at 7.82. In other words for every 100,000 Veracyte shares traded daily on the market, roughly 7820 shares are currently held short.

However Veracyte's short interest can also be evaluated against the total number of Veracyte shares, or, against the total number of tradable Veracyte shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Veracyte's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Veracyte shares in existence, roughly 60 shares are currently held short) or 0.0611% of the tradable shares (for every 100,000 tradable Veracyte shares, roughly 61 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Veracyte.

Find out more about how you can short Veracyte stock.

Veracyte share dividends

We're not expecting Veracyte to pay a dividend over the next 12 months.

Veracyte share price volatility

Over the last 12 months, Veracyte's shares have ranged in value from as little as $13.9 up to $44.64. A popular way to gauge a stock's volatility is its "beta".

VCYT.US volatility(beta: 0.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Veracyte's is 0.6233. This would suggest that Veracyte's shares are less volatile than average (for this exchange).

Veracyte overview

Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test for assessing risk of distant recurrence. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson Innovation and the Lung Cancer Initiative at Johnson & Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and a collaboration with Johnson & Johnson Services, Inc. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site